NASDAQ:GNCAGenocea Biosciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Genocea Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.66 0.00 (0.00 %) (As of 04/3/2020 04:00 PM ET) Add Compare Share Today's Range$1.57Now: $1.66▼$1.7550-Day Range$1.26MA: $1.86▼$2.4152-Week Range$1.10Now: $1.66▼$11.28Volume122,031 shsAverage Volume294,576 shsMarket Capitalization$45.88 millionP/E RatioN/ADividend YieldN/ABeta2.11 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. Its lead immuno-oncology program is GEN-009, an adjuvanted neoantigen peptide vaccine candidate, which is in preclinical stage, designed to direct a patient's immune system to attack tumor. The company is also seeking partners to develop cancer vaccines targeting tumor-associated antigens and a vaccine targeting cancers caused by Epstein-Barr virus. Genocea Biosciences, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingGenocea Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.33, Genocea Biosciences has a potential upside of 883.9% from its current price of $1.66.Amount of Analyst CoverageGenocea Biosciences has received no research coverage in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesGenocea Biosciences has received 369 “outperform” votes. (Add your “outperform” vote.)Underperform VotesGenocea Biosciences has received 293 “underperform” votes. (Add your “underperform” vote.)Community SentimentGenocea Biosciences has received 55.74% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Genocea Biosciences and other stocks. Vote “Outperform” if you believe GNCA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GNCA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldGenocea Biosciences does not currently pay a dividend.Dividend GrowthGenocea Biosciences does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Genocea Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.33% of the stock of Genocea Biosciences is held by insiders.Percentage Held by Institutions53.58% of the stock of Genocea Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Genocea Biosciences are expected to decrease by -2.17% in the coming year, from ($1.38) to ($1.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Genocea Biosciences is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Genocea Biosciences is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGenocea Biosciences has a P/B Ratio of 1.87. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.46 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GNCA Previous Symbol CUSIPN/A CIK1457612 Webhttp://www.genocea.com/ Phone617-876-8191Debt Debt-to-Equity Ratio0.77 Current Ratio6.62 Quick Ratio6.62Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.89 per share Price / Book1.87Profitability EPS (Most Recent Fiscal Year)($2.09) Net Income$-38,950,000.00 Net MarginsN/A Return on Equity-150.72% Return on Assets-67.80%Miscellaneous Employees61 Outstanding Shares27,640,000Market Cap$45.88 million Next Earnings Date5/5/2020 (Estimated) OptionableOptionable Receive GNCA News and Ratings via Email Sign-up to receive the latest news and ratings for GNCA and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:GNCA Rates by TradingView Genocea Biosciences (NASDAQ:GNCA) Frequently Asked Questions How has Genocea Biosciences' stock been impacted by COVID-19 (Coronavirus)? Genocea Biosciences' stock was trading at $1.83 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, GNCA stock has decreased by 9.3% and is now trading at $1.66. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Genocea Biosciences? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genocea Biosciences in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Genocea Biosciences. When is Genocea Biosciences' next earnings date? Genocea Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Genocea Biosciences. How were Genocea Biosciences' earnings last quarter? Genocea Biosciences Inc (NASDAQ:GNCA) released its quarterly earnings data on Thursday, February, 13th. The biotechnology company reported ($0.34) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.39) by $0.05. View Genocea Biosciences' earnings history. What price target have analysts set for GNCA? 4 Wall Street analysts have issued 12 month target prices for Genocea Biosciences' stock. Their forecasts range from $7.00 to $32.00. On average, they expect Genocea Biosciences' stock price to reach $16.33 in the next year. This suggests a possible upside of 883.9% from the stock's current price. View analysts' price targets for Genocea Biosciences. What are Wall Street analysts saying about Genocea Biosciences stock? Here are some recent quotes from research analysts about Genocea Biosciences stock: 1. According to Zacks Investment Research, "Genocea Biosciences, Inc. is involved in developing vaccines. The company's proprietary discovery platform consists of AnTigen Lead Acquisition System which designs vaccines that stimulate T cell immunity. Its product portfolio which are in different clinical trials consist of GEN-003, HSV-2 infections, GEN-004 and HSV-2 prophylaxis and malaria. Genocea Biosciences, Inc. is headquartered in Cambridge, Massachusetts. " (2/20/2020) 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and are lowering our price target to $32 from $42 to reflect the recent dilution, and fully diluted share count from the company’s equity raise." (7/25/2019) Has Genocea Biosciences been receiving favorable news coverage? Press coverage about GNCA stock has trended very negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Genocea Biosciences earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutGenocea Biosciences. Are investors shorting Genocea Biosciences? Genocea Biosciences saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 320,300 shares, an increase of 34.5% from the February 13th total of 238,100 shares. Based on an average daily volume of 262,000 shares, the short-interest ratio is presently 1.2 days. Currently, 2.0% of the shares of the company are sold short. View Genocea Biosciences' Current Options Chain. Who are some of Genocea Biosciences' key competitors? Some companies that are related to Genocea Biosciences include Tcr2 Therapeutics (TCRR), Cabaletta Bio (CABA), Jounce Therapeutics (JNCE), X4 Pharmaceuticals (XFOR), Verona Pharma (TARA), La Jolla Pharmaceutical (LJPC), Dyadic International (DYAI), Windtree Therapeutics (WINT), Eiger Biopharmaceuticals (EIGR), Brainstorm Cell Therapeutics (BCLI), Vaxart (VXRT), Fennec Pharmaceuticals (FENC), Cidara Therapeutics (CDTX), LogicBio Therapeutics (LOGC) and Solid Biosciences (SLDB). What other stocks do shareholders of Genocea Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Genocea Biosciences investors own include Hawkins (HWKN), CA (CA), Endologix (ELGX), Chipotle Mexican Grill (CMG), BlackRock (BLK), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Hudson Technologies (HDSN), Accenture (ACN) and AutoZone (AZO). Who are Genocea Biosciences' key executives? Genocea Biosciences' management team includes the following people: Mr. William D. Clark M.B.A., Pres, CEO & Director (Age 50)Dr. Jessica Baker Flechtner, Chief Scientific Officer (Age 47)Dr. George R. Siber M.D., Ph.D., Chairman of Scientific Advisory Board & Exec. Director (Age 74)Mr. Michael Alfieri, VP of Fin., Principal Financial Officer & Principal Accounting Officer (Age 54)Ms. Pamela Carroll, Sr. VP of Immun-Oncology (Age 55) What is Genocea Biosciences' stock symbol? Genocea Biosciences trades on the NASDAQ under the ticker symbol "GNCA." How do I buy shares of Genocea Biosciences? Shares of GNCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Genocea Biosciences' stock price today? One share of GNCA stock can currently be purchased for approximately $1.66. How big of a company is Genocea Biosciences? Genocea Biosciences has a market capitalization of $45.88 million. The biotechnology company earns $-38,950,000.00 in net income (profit) each year or ($2.09) on an earnings per share basis. Genocea Biosciences employs 61 workers across the globe. View additional information about Genocea Biosciences. What is Genocea Biosciences' official website? The official website for Genocea Biosciences is http://www.genocea.com/. How can I contact Genocea Biosciences? Genocea Biosciences' mailing address is 100 ACORN PARK DRIVE, CAMBRIDGE MA, 02140. The biotechnology company can be reached via phone at 617-876-8191 or via email at [email protected] This page was last updated on 4/4/2020 by MarketBeat.com StaffFeatured Article: What is the Shanghai Stock Exchange Composite Index?
